TruScreen Raises Initial $600,000 in Share Placement

NZX/ASX Announcement


3 March 2023

TruScreen Raises Initial $600,000 in Share Placement

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that further to the announcement of
17 February 2023 “Truscreen to lodge a pro rata renounceable rights issue”, the Company has
received firm commitments from a number of investors for an initial Placement of 20,000,000 shares
at NZ$0.03 each to raise $600,000, before costs.
The shares will be issued under its existing 15% placement capacity. This Placement is in addition to
the Oversubscription Bookbuild which will take place on 15
th
and 16
th
March 2023.
Tony Ho Chairman commented, “we are pleased with the strong support we have received at the start
of this capital raise, and encourage shareholders to ensure their applications are completed before
the closing date on 15 March 2023”.
In the event shareholders have not received application forms please contact the share registry Link
Market Services:
enquiries@linkmarketservices.co.nz
T 64 9 375 5998 or the Company Secretary, contact details
below.
This announcement has ben approved by the Board.
Ends
Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/